Get started
Author

Jeffrey Meltzer

Observed names: J. I. Meltzer, J. Meltzer, Jeff Meltzer
OpenAlex ID: A5111778367
Visualization and Transport of Positron Emission from Proton Activation in vivo
1978 · G. W. Bennett, J. O. Archambeau, et al. · Science · 97
177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
2021 · Oliver Sartor, Christian la Fougère, et al. · Journal of Nuclear Medicine · 30
PDF
The development of metastases within a field of previous irradiation: A case report
1981 · J. Meltzer, S. A. Ahmed, et al. · Cancer · 15
PDF
Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE)
2024 · Celestia S. Higano, Sabina Dizdarevic, et al. · Cancer · 10
PDF
Interim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer
2018 · F. Saad, K.N. Chi, et al. · Annals of Oncology · 6
1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
2023 · B. Tombal, P.J. Goebell, et al. · Annals of Oncology · 4
PDF
Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.
2022 · Nicholas D. James, Daniel Heinrich, et al. · Journal of Clinical Oncology · 4
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study
2025 · Joe M. O’Sullivan, Daniel Heinrich, et al. · British Journal of Cancer · 3
PDF
The development of metastases within a field of previous irradiation
1982 · Hal G. Bingham, J. Meltzer, et al. · Plastic & Reconstructive Surgery · 3
Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).
2020 · A. Oliver Sartor, Christian la Fougère, et al. · Journal of Clinical Oncology · 2
Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.
2020 · Celestia S. Higano, Lauren C Harshman, et al. · Journal of Clinical Oncology · 2
Induced radioactivity in patients from betatron irradiation
1981 · G. W. Bennett, R. Dobert, et al. · British Journal of Radiology · 2
1394P Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study
2022 · J. O'Sullivan, D. Heinrich, et al. · Annals of Oncology · 1
PDF
Real-world characteristics of long-term survivors with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An analysis of the global REASSURE study.
2026 · Saby George, Sabina Dizdarevic, et al. · Journal of Clinical Oncology
2401P Combined treatment with radium-223 (RAD) and enzalutamide (ENZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Insights from the global REASSURE study
2025 · I. Jan de Jong, C.N. Sternberg, et al. · Annals of Oncology
Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study.
2025 · Alton Oliver Sartor, Sabina Dizdarevic, et al. · Journal of Clinical Oncology
Abstract C160: Baseline characteristics, safety, and efficacy of Radium-223 in metastatic castration resistant prostate cancer by race: Insights from the REASSURE US subset
2024 · Peter S. Conti, Oliver Sartor, et al. · Cancer Epidemiology Biomarkers & Prevention
Comparing patient profiles and treatment outcomes with radium-223 (223Ra) in real-world settings: Academic vs. community practice in the US—Insights from the REASSURE study.
2024 · Celestia S. Higano, Robert K. Brookland, et al. · Journal of Clinical Oncology
PDF
Safety outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223 following external beam radiation therapy: REASSURE US subset.
2024 · A. Oliver Sartor, Peter Conti, et al. · Journal of Clinical Oncology
PDF
Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study.
2023 · Daniel Y. Song, Saby George, et al. · Journal of Clinical Oncology
Safety And Clinical Outcomes Of Radium-223 With Concomitant Radiotherapy Or Subsequent Treatment With The Investigational Agent 177Lu-PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: An Interim Analysis Of The REASSURE Study
2020 · D. Song, S.H. Zimberg, et al. · International Journal of Radiation Oncology*Biology*Physics
In vivo localization of induced activity resulting from betatron irradiation
1978 · Jeffrey Meltzer, Gerald W. Bennett, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
Works count: 22
Citation count: 179
H-index: 5
I10-index: 4
Year
Topic
Type